Risk of hepatocellular carcinoma with tenofovir versus entecavir in chronic hepatitis B

Won-Mook Choi¹, Jonggi Choi¹, Grace Lai-Hung Wong², Seungbong Han³, Young-Suk Lim⁴

Affiliations

¹ Department of Gastroenterology, Liver Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, South Korea.
² Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, China.
³ Department of Applied Statistics, Gachon University, Seongnam-si, South Korea.
⁴ Department of Gastroenterology, Liver Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, South Korea. Electronic address: limys@amc.seoul.kr.

PMID: 33444532
DOI: 10.1016/S2468-1253(20)30372-1

Comment

Risk of hepatocellular carcinoma with tenofovir versus entecavir in chronic hepatitis B

Won-Mook Choi et al. Lancet Gastroenterol Hepatol. 2021 Feb.

. 2021 Feb;6(2):87.

doi: 10.1016/S2468-1253(20)30372-1.

Authors

Won-Mook Choi¹, Jonggi Choi¹, Grace Lai-Hung Wong², Seungbong Han³, Young-Suk Lim⁴

Affiliations

¹ Department of Gastroenterology, Liver Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, South Korea.
² Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, China.
³ Department of Applied Statistics, Gachon University, Seongnam-si, South Korea.
⁴ Department of Gastroenterology, Liver Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, South Korea. Electronic address: limys@amc.seoul.kr.

PMID: 33444532
DOI: 10.1016/S2468-1253(20)30372-1

No abstract available

PubMed Disclaimer

Comment in

Risk of hepatocellular carcinoma with tenofovir versus entecavir in chronic hepatitis B - Authors' reply.
Tseng CH, Hsu YC, Nguyen MH. Tseng CH, et al. Lancet Gastroenterol Hepatol. 2021 Feb;6(2):87-88. doi: 10.1016/S2468-1253(20)30395-2. Lancet Gastroenterol Hepatol. 2021. PMID: 33444533 No abstract available.

Comment on

Hepatocellular carcinoma incidence with tenofovir versus entecavir in chronic hepatitis B: a systematic review and meta-analysis.
Tseng CH, Hsu YC, Chen TH, Ji F, Chen IS, Tsai YN, Hai H, Thuy LTT, Hosaka T, Sezaki H, Borghi JA, Cheung R, Enomoto M, Nguyen MH. Tseng CH, et al. Lancet Gastroenterol Hepatol. 2020 Dec;5(12):1039-1052. doi: 10.1016/S2468-1253(20)30249-1. Epub 2020 Sep 30. Lancet Gastroenterol Hepatol. 2020. PMID: 33007228

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Risk of hepatocellular carcinoma with tenofovir versus entecavir in chronic hepatitis B

Affiliations

Risk of hepatocellular carcinoma with tenofovir versus entecavir in chronic hepatitis B

Authors

Affiliations

Comment in

Comment on

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical